Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
德国多发性骨髓瘤多中心研究组 (GMMG) HD6 试验的原理和设计:一项随机 III 期试验,旨在研究埃罗妥珠单抗在 VRD 诱导/巩固治疗和来那度胺维持治疗中对新诊断多发性骨髓瘤患者的影响。
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-019-5600-x
Salwender, Hans; Bertsch, Uta; Weisel, Katja; Duerig, Jan; Kunz, Christina; Benner, Axel; Blau, Igor W; Raab, Marc Steffen; Hillengass, Jens; Hose, Dirk; Huhn, Stefanie; Hundemer, Michael; Andrulis, Mindaugas; Jauch, Anna; Seidel-Glaetzer, Andrea; Lindemann, Hans-Walter; Hensel, Manfred; Fronhoffs, Stefan; Martens, Uwe; Hansen, Timon; Wattad, Mohammed; Graeven, Ullrich; Munder, Markus; Fenk, Roland; Haenel, Mathias; Scheid, Christof; Goldschmidt, Hartmut